Interim results of Ofatumumab phase II study in MS announced
Interim results of Ofatumumab phase II study in MS announced
Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).
A total of 38 patients were included in the trial, of which 12 patients received placebo and 26 patients received ofatumumab intravenously. Patients were treated with ofatumumab at the dose levels of 100 mg, 300 mg or 700 mg and followed for 24 weeks. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1403 Views
-
Last post by frodo
-
- 0 Replies
- 1041 Views
-
Last post by frodo
-
- 0 Replies
- 1359 Views
-
Last post by frodo
-
- 0 Replies
- 1812 Views
-
Last post by NHE
-
- 2 Replies
- 4599 Views
-
Last post by DIM
-
- 1 Replies
- 3331 Views
-
Last post by Tif
-
- 0 Replies
- 2631 Views
-
Last post by NHE
-
- 1 Replies
- 1300 Views
-
Last post by Scott1
-
- 1 Replies
- 2080 Views
-
Last post by frodo